271. Ankylosing spondylitis Clinical trials / Disease details
Clinical trials : 574 / Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100048756 | 2021-07-19 | 2021-07-16 | Yunpi Yishen Tongdu for active ankylosing spondylitis: a prospective cohort study | Yunpi Yishen Tongdu for active ankylosing spondylitis: a prospective cohort study | ankylosing spondylitis | Non-exposed group: Meloxicam tablets, once a day, one tablet at a time. According to the patient's condition, sulfasalazine tablets and other recommended anti-rheumatic drugs for the treatment of AS/SpA can be added.;Exposed group:On the basis of the non-exposure group, Yunpi Yishen Jiedu Tongdu granules were added. ; | Zhejiang University of Traditional Chinese Medicine | NULL | Pending | 18 | 65 | Both | Non-exposed group:125;Exposed group:125; | N/A | China |
| 2 | ITMCTR2100005056 | 2021-07-19 | 2021-07-16 | Yunpi Yishen Tongdu for active ankylosing spondylitis: a prospective cohort study | Yunpi Yishen Tongdu for active ankylosing spondylitis: a prospective cohort study | ankylosing spondylitis | Non-exposed group: Meloxicam tablets, once a day, one tablet at a time. According to the patient's condition, sulfasalazine tablets and other recommended anti-rheumatic drugs for the treatment of AS/SpA can be added.;Exposed group:On the basis of the non-exposure group, Yunpi Yishen Jiedu Tongdu granules were added. ; | Zhejiang University of Traditional Chinese Medicine | NULL | Pending | 18 | 65 | Both | Non-exposed group:125;Exposed group:125; | N/A | China |
| 3 | NCT02183168 (ClinicalTrials.gov) | July 2001 | 4/7/2014 | Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis | A Randomized, Open Label, 3-arm Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis | Spondylitis, Ankylosing | Drug: Meloxicam suppository;Drug: Meloxicam tablet;Drug: Indomethacin | Boehringer Ingelheim | NULL | Completed | N/A | N/A | Both | 192 | Phase 3 | NULL |